Mezigdomide is an investigational oral CELMoD being developed by Bristol Myers Squibb for the treatment of RRMM. As a next-generation immunomodulatory drug (IMiD), mezigdomide is designed to address treatment resistance and improve outcomes in patients previously exposed to established therapies. 

Bristol Myers Squibb is advancing mezigdomide through the Phase III SUCCESSOR programs in RRMM. Positive interim results from SUCCESSOR-2 demonstrated a significant progression-free survival benefit, marking the second positive pivotal readout for the company's oral CELMoD platform and reinforcing mezigdomide's potential as a next-generation treatment option in RRMM. In parallel, the ongoing SUCCESSOR-1 study is evaluating a mezigdomide-based combination against a pomalidomide-based regimen and is expected to further clarify the clinical advantages of CELMoDs over established IMiDs. Additionally, Bristol Myers Squibb has expanded the development of mezigdomide through a clinical trial collaboration with Karyopharm Therapeutics to evaluate the combination of mezigdomide, selinexor, and dexamethasone in RRMM. 

According to the company's latest corporate presentation, pivotal data from the SUCCESSOR program are anticipated in 2027, further supporting mezigdomide's potential to become an important future treatment option in multiple myeloma.

Key Efficacy Highlights form ASCO 2026:

• MeziKd reduced the risk of disease progression or death by 52% vs. Kd (HR 0.48; 95% CI: 0.36–0.63; p<0.0001)

• Median PFS: 18.0 months with MeziKd vs. 8.3 months with Kd

• ORR: 80.2% with MeziKd vs. 53.4% with Kd

• CR+: 26.7% vs. 8.9% (approximately threefold higher with MeziKd)

• VGPR+: 60.1% vs. 30.9%

• 12-month duration of response: 72% vs 54%

• Median PFS2: 23.6 months vs. 13.0 months (HR 0.53), demonstrating sustained benefit beyond subsequent therapies

• Overall survival: Positive trend favoring MeziKd (HR 0.79), with deaths reported in 21.5% vs. 26.7% of patients

• Median overall survival was not yet reached

Key Safety Highlights from ASCO 2026: 

• Any-grade infections: 72.9% vs. 53.8%

• Grade 3/4 treatment-emergent adverse events (TEAEs): 83.7% vs. 56.5% 

• Grade 3/4 neutropenia: 61.1% with MeziKd vs. 9.1% with Kd; generally manageable with dose modifications and/or G-CSF support

• Grade 3/4 thrombocytopenia: 39.2% vs. 22.6%

• Grade 4 infections: 5.6% vs. 0.5%; infrequent overall and manageable with standard care

• Infections 34.0% vs. 15.6% 

• Fatal infections: 2.4% vs. 1.1%

• Grade 5 TEAEs: 7.3% vs. 4.3%, with most occurring in the setting of disease progression

• Treatment discontinuations due to AEs: Infrequent in both arms

KOL insights

“The SUCCESSOR-2 findings support oral mezigdomide plus weekly carfilzomib as a potential new standard of care for RRMM, offering significant efficacy benefits, a manageable safety profile, and a convenient treatment approach suitable for both academic and community practice settings.” – Expert Opinion

“CELMoDs work harder, faster, and more effectively than traditional IMiDs. Anything an IMiD can do, a CELMoD can do better; not only in terms of efficacy, but also with respect to safety and tolerability, which is critically important for RRMM patients. As the evidence continues to evolve, CELMoDs have the potential to replace IMiDs in the treatment landscape.”– Expert Opinion

Conclusion-

Multiple myeloma predominantly affects older adults, with less than 1% of cases diagnosed in individuals younger than 35 years. The United States multiple myeloma market, currently dominated by daratumumab (DARZALEX)-based regimens, continues to evolve with the emergence of newer next-generation therapies aimed at overcoming resistance and improving long-term outcomes. 

Among the IMiDs, BMS lenalidomide historically dominated the multiple myeloma market across the seven major markets and has been widely used across multiple lines of therapy, either as monotherapy or in combination regimens. However, following the expiration of key patents and the entry of generic versions beginning in 2022, the market landscape for lenalidomide has become increasingly competitive, although it continues to remain an important backbone therapy in multiple myeloma treatment. 

Now BMS is developing a next-generation CELMoD, mezigdomide which is emerging as a promising addition to the RRMM treatment paradigm, with the potential to deliver deeper and more durable responses than traditional IMiDs. These findings underscore its potential to become an important future treatment option and a meaningful competitor in an increasingly dynamic multiple myeloma market.